Researchers at Washington University School of Medicine in St. Louis are developing methods to track molecular events in the body to diagnose disease long before symptoms appear and to predict the effectiveness of drug therapies.

"Molecular imaging combines the latest in imaging technology with the power of molecular biology," says David Piwnica-Worms, M.D., Ph.D., director of the Molecular Imaging Center at the Mallinckrodt Institute of Radiology.

"We believe that molecular imaging will one day enable us to diagnose specific molecular events of cancer, neurologic disease or inflammation earlier in the course of disease, and that this will help doctors identify the most effective therapy for individual patients."

Investigators at the Center are using molecular imaging to study protein-protein interactions, immune cells attacking a tumor, and the course of a viral infection and its response to antiviral therapy. Other researchers are developing a means to noninvasively predict the effectiveness of particular chemotherapy drugs in patients with advanced lung cancer. The investigators are studying lung tumors for ways to image the activity of a protein that pumps certain anticancer drugs out of tumor cells, rendering the drugs ineffective for those individuals.

Positron emission tomography (PET) is one example of molecular imaging technology already in use clinically. PET scans are used, for instance, to detect the spread of certain cancers. Patients are given a form of sugar-glucose-that contains a weak radioactive label. The labeled sugar is taken up more rapidly by tumor cells than by normal cells because the tumor cells are growing at a faster rate. PET-scan imaging reveals this higher level of uptake, thereby providing a non-surgical means of detecting an otherwise hidden tumor.

SOURCE:
Washington University School of Medicine (http://www.wustl.edu)